Market Access

In order to gain market access in pharma and remain competitive, pharmaceutical and medical technology manufacturers must be able to demonstrate clinical and economic evidence to providers, healthcare decision-makers and payers.

In the past, market access for a drug depended almost exclusively on efficacy and safety. These factors are still critical, but today, clinical differentiation and its effects on cost effectiveness is gaining importance. Today, more than ever, pharmaceutical companies must demonstrate how a new drug improves patient outcomes, reduces the burden of the healthcare system as a whole and is worth its price. To satisfy these criteria, pharmaceutical manufacturers have gradually expanded their business “beyond the pill” to build an evidence based strategy and therefore a stronger value story for payers.

For payers and market access stakeholders, the drug value proposition encompasses the optimal combination of disease need, clinical efficacy and economic impact that achieves market access at an optimal price, by validating and communicating the need for treatment and the value of utilizing the drug in question. To do so, market access activities have expanded beyond pricing and reimbursement, and include other elements in the drug development continuum such as:

• Regulatory
• Supply Chain and channels
• Training and education
• Stakeholders and key opinion leader (“KOL”) management
• Financing/Investors

We can help you navigate the increasingly complicated legislative environment. Each stakeholder has their own particular interest in a product, and we can help you communicate the value of your product to stakeholders.